Cellerant Therapeutics is a clinical stage biotechnology company based in San Carlos, California that develops cell- and antibody-based immunotherapies for hematological malignancies and other blood-related disorders. Cellerant's pipeline includes Romyelocel-L (CLT-008) and two antibody drug conjugates (ADC), CLT030 and CSC012-ADC.
Romyelocel-L is an off-the-shelf universal cell therapy intended to prevent infections during neutropenia, a severe side effect of many chemotherapy regimens, particularly for acute myeloid leukemia (AML) and other blood related disorders. It has the potential to significantly reduce the risk of serious infection. Romyelocel-L is manufactured from hematopoietic stem cells obtained from screened and tested healthy donors. The stem cells are then expanded and differentiated into myeloid progenitor cells (MPCs) and is then cryopreserved. The FDA has granted Romyelocel-L Regenerative Medicine Advance Therapy (RMAT) designation for the prevention of neutropenia in AML. Cellerant plans to launch Phase 3 trials in 2019. The therapy is also being tested for efficacy to treat neutropenia in acute radiation syndrome (ARS) and increase tolerance of organ transplants.
CLT030, which is in development and is expected to enter Phase 1 clinical trials in 2019, is an ADC with a highly potent, DNA-binding payload, for the treatment of AML. It targets C-type lectin molecules (CLEC12A), a cell surface marker highly expressed on leukemic stem cells. It has shown promising efficacy in animal models.
CSC012 is a lead Interleukin-1 receptor accessory protein (IL1RAP) targeting antibody that has been selected and conjugated with a series of linker payloads to generate the antibody drug conjugate, CSC012-ADC. In vitro and in vivo results have demonstrated that it is a potent ADC and an excellent candidate for further development as a targeted treatment for AML.
VP Manufacturing & Process Sciences
Irving L. Weissman
Jagath Reddy Junutula
VP Antibody Discovery & Development
President & CEO
Timothy C. Fong
Vanessa Love Van Pell
Cellerant Therapeutics, Inc. Announces FDA Grants Regenerative Medicine Advanced Therapy (RMAT) Designation for Romyelocel-L to Prevent Infections During Neutropenia
Cellerant Therapeutics, Inc. Presents Phase 2 Results Showing CLT-008 Significantly Reduces Risk of Infections in AML Patients Undergoing Standard Induction Chemotherapy
Documentaries, videos and podcasts
October 18, 2018
- Cluster: BiotechnologyA cluster of topics related to biotechnology.
- Cluster: Stem cell technologyTechnology used for isolating, generating, growing and controlling the differentiation of stem cells into specialized cells and the application of stem cell technology for medical and non-medical purposes such as producing meat through cellular agriculture.
- BiotechnologyBiolotechnology can refer to the application of science and technology to living organisms or the use of living organisms, their parts, products or models thereof to solve a problem, produce knowledge or produce goods and services. Biotechnology may involve the alteration of living or non-living materials.
- Stem cellStem cells are self-renewing cells that have the potential to become multiple different cell types in the body. Stem cells are found in developing embryos. Adult stem cells maintain and repair tissues throughout life. Induced pluripotent stem cells are a type of stem cell derived from adult cells that are reprogrammed in the lab.